[EN] SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME<br/>[FR] INHIBITEURS SÉLECTIFS DE L'INFLAMMASOME NLRP3
申请人:NODTHERA LTD
公开号:WO2019025467A1
公开(公告)日:2019-02-07
The present disclosure relates to compounds of Formula (I): (I); and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as autoinflammatory and autoimmune diseases and cancers.
The present invention relates to Tetrahydrofuropyridones compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
本发明涉及四氢呋喃吡啶酮化合物,用作HIF脯氨酸羟化酶抑制剂,用于治疗贫血等疾病。
US8471024B2
申请人:——
公开号:US8471024B2
公开(公告)日:2013-06-25
Regiodivergent C−H and Decarboxylative C−C Alkylation by Ruthenium Catalysis:
<i>ortho</i>
versus
<i>meta</i>
Position‐Selectivity
作者:Korkit Korvorapun、Marc Moselage、Julia Struwe、Torben Rogge、Antonis M. Messinis、Lutz Ackermann
DOI:10.1002/anie.202007144
日期:2020.10.12
Ruthenium(II)biscarboxylate complexes enabled the selectivealkylation of C−H and C−C bonds at the ortho‐ or meta‐position. ortho‐C−HAlkylations were achieved with 4‐, 5‐ as well as 6‐membered halocycloalkanes. Furthermore, the judicious choice of the directing group allowed for a full control of ortho‐/meta‐selectivities. Detailed mechanistic studies by experiment and computation were performed and